Thoratec Takes Over REVIVE-IT LVAD Trial From HeartWare
This article was originally published in The Gray Sheet
The pilot trial, cosponsored by NIH, will give ventricular assist devices a chance to prove their worth in heart failure patients not yet in the final stage of their illness.
You may also be interested in...
A recent analysis of the cost effectiveness of ventricular assist devices used as destination therapy for heart failure suggests room for improvement.
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.
HeartWare International Inc.’s HeartWare Ventricular Assist System has finally gained PMA approval, but FDA labeling requirements have sparked questions from analysts.